NEW YORK (GenomeWeb News) – Trovagene announced late on Tuesday the pricing of a public offering of 1.15 million units and said that its shares will begin trading on the Nasdaq Capital Market today under ticker symbol "TROV".

In connection with its listing on the Nasdaq, the San Diego-based molecular diagnostics firm has effected a one-for-six reverse stock split.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.